Successful Treatment of Recurrent Primary Sclerosing Cholangitis After Orthotopic Liver Transplantation with Oral Vancomycin

Overview

Journal Case Rep Transplant

Publisher Wiley

Specialty General Surgery

Date 2013 Mar 20

PMID 23509657

Citations 23

Authors

Yinka K Davies

Cynthia J Tsay

Dario V Caccamo

Kathleen M Cox

Ricardo O Castillo

Kenneth L Cox

Affiliations

Soon will be listed here.

Abstract

Primary sclerosing cholangitis (PSC) is a progressive, cholestatic disease of the liver that is marked by inflammation of the bile ducts and damage to the hepatic biliary tree. Approximately 60-70% of patients also have inflammatory bowel disease and progression of PSC can lead to ulcerative colitis and cirrhosis of the liver. Due to limited understanding of the etiology and mechanism of PSC, the only existing treatment option is orthotopic liver transplantation (OLT); however, recurrence of PSC, after OLT is estimated to be between 5% and 35%. We discuss the successful treatment of a pediatric patient, with recurrent PSC, after OLT with oral Vancomycin.

Citing Articles

Recurrence of Primary Disease After Adult Liver Transplant - Risk Factors, Early Diagnosis, Management, and Prevention.

Mehtani R, Rathi S J Clin Exp Hepatol. 2024; 14(6):101432.

PMID: 38975605 PMC: 11222954. DOI: 10.1016/j.jceh.2024.101432.

Complete Biochemical Remission With Oral Vancomycin in a Patient With Primary Sclerosing Cholangitis and High Serum Immunoglobulin G4 Levels.

Sohal A, Kowdley K ACG Case Rep J. 2024; 11(1):e01256.

PMID: 38236497 PMC: 10793982. DOI: 10.14309/crj.0000000000001256.

Current Therapies for Cholestatic Diseases.

Mendez-Sanchez N, Coronel-Castillo C, Ordonez-Vazquez A Biomedicines. 2023; 11(6).

PMID: 37371808 PMC: 10296345. DOI: 10.3390/biomedicines11061713.

Role of intestinal flora in primary sclerosing cholangitis and its potential therapeutic value.

Li Z, Gou H, Zhang Y, Song X, Zhang L World J Gastroenterol. 2022; 28(44):6213-6229.

PMID: 36504550 PMC: 9730442. DOI: 10.3748/wjg.v28.i44.6213.

Systematic review: microbial manipulation as therapy for primary sclerosing cholangitis.

Bogatic D, Bryant R, Lynch K, Costello S Aliment Pharmacol Ther. 2022; 57(1):23-36.

PMID: 36324251 PMC: 10092549. DOI: 10.1111/apt.17251.

References

Siedlar M, Szczepanik A, Wieckiewicz J, Pituch-Noworolska A, Zembala M . Vancomycin down-regulates lipopolysaccharide-induced tumour necrosis factor alpha (TNF alpha) production and TNF alpha-mRNA accumulation in human blood monocytes. Immunopharmacology. 1997; 35(3):265-71. DOI: 10.1016/s0162-3109(96)00156-7. View

Rosen C, Nagorney D, Wiesner R, Coffey Jr R, Larusso N . Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg. 1991; 213(1):21-5. PMC: 1358305. DOI: 10.1097/00000658-199101000-00004. View

Cox K, Cox K . Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1998; 27(5):580-3. DOI: 10.1097/00005176-199811000-00015. View

Wiesner R, Grambsch P, Dickson E, Ludwig J, MacCarty R, Hunter E . Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology. 1989; 10(4):430-6. DOI: 10.1002/hep.1840100406. View

Di Febo G, Calabrese C, Matassoni F . New trends in non-absorbable antibiotics in gastrointestinal disease. Ital J Gastroenterol. 1992; 24(9 Suppl 2):10-3. View

Feldstein A, Perrault J, El-Youssif M, Lindor K, Freese D, Angulo P . Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology. 2003; 38(1):210-7. DOI: 10.1053/jhep.2003.50289. View

Brandsaeter B, Isoniemi H, Broome U, Olausson M, Backman L, Hansen B . Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol. 2004; 40(5):815-22. DOI: 10.1016/j.jhep.2004.01.002. View

Olsson R, Danielsson A, Jarnerot G, Lindstrom E, Loof L, Rolny P . Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology. 1991; 100(5 Pt 1):1319-23. View

Farrant J, Hayllar K, Wilkinson M, Karani J, Portmann B, Westaby D . Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology. 1991; 100(6):1710-7. DOI: 10.1016/0016-5085(91)90673-9. View

10.

Mieli-Vergani G, Vergani D . Unique features of primary sclerosing cholangitis in children. Curr Opin Gastroenterol. 2010; 26(3):265-8. DOI: 10.1097/MOG.0b013e3283388f5b. View

11.

Nikolaidis N, Giouleme O, Tziomalos K, Patsiaoura K, Kazantzidou E, Voutsas A . Small-duct primary sclerosing cholangitis. A single-center seven-year experience. Dig Dis Sci. 2005; 50(2):324-6. DOI: 10.1007/s10620-005-1604-2. View

12.

Ponsioen C, Vrouenraets S, Prawirodirdjo W, Rajaram R, Rauws E, Mulder C . Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut. 2002; 51(4):562-6. PMC: 1773389. DOI: 10.1136/gut.51.4.562. View

13.

Wee A, Ludwig J, Coffey Jr R, Larusso N, Wiesner R . Hepatobiliary carcinoma associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hum Pathol. 1985; 16(7):719-26. DOI: 10.1016/s0046-8177(85)80158-1. View

14.

Tischendorf J, Meier P, Strassburg C, Klempnauer J, Hecker H, Manns M . Characterization and clinical course of hepatobiliary carcinoma in patients with primary sclerosing cholangitis. Scand J Gastroenterol. 2006; 41(10):1227-34. DOI: 10.1080/00365520600633495. View

15.

Chapman R, Fevery J, Kalloo A, Nagorney D, Boberg K, Shneider B . Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010; 51(2):660-78. DOI: 10.1002/hep.23294. View

16.

Davies Y, Cox K, Abdullah B, Safta A, Terry A, Cox K . Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr. 2008; 47(1):61-7. DOI: 10.1097/MPG.0b013e31816fee95. View

17.

Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A . Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996; 38(4):610-5. PMC: 1383124. DOI: 10.1136/gut.38.4.610. View

18.

Abu-Elmagd K, Selby R, Iwatsuki S, Fung J, Tzakis A, Todo S . Cholangiocarcinoma and sclerosing cholangitis: clinical characteristics and effect on survival after liver transplantation. Transplant Proc. 1993; 25(1 Pt 2):1124-5. PMC: 2965527. View

19.

Abu-Elmagd K, Malinchoc M, Dickson E, Fung J, Murtaugh P, Langworthy A . Efficacy of hepatic transplantation in patients with primary sclerosing cholangitis. Surg Gynecol Obstet. 1993; 177(4):335-44. PMC: 2729197. View

20.

Nashan B, Schlitt H, Tusch G, Oldhafer K, Ringe B, Wagner S . Biliary malignancies in primary sclerosing cholangitis: timing for liver transplantation. Hepatology. 1996; 23(5):1105-11. DOI: 10.1002/hep.510230526. View